Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkFive-Year Outcomes of FOLFIRINOX vs. Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial

The final results of this randomized clinical trial of 493 patients with pancreatic ductal adenocarcinoma (PDAC) showed that treatment with modified FOLFIRINOX as opposed to gemcitabine significantly increased overall survival (median survival, 53.5 vs. 35.5 months). Younger age, well-differentiated tumors, lower-stage tumors, larger-volume centers, and finishing the prescribed course of therapy all predicted better survival; early disease relapse was an adverse prognostic factor for overall survival from relapse.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form